UNIHEALTH
Unihealth Hosp share price & financials
- Price
- ₹566
- Market cap
- ₹1.1k Cr
- Sector
- Healthcare
- Calls analysed
- 3
Unihealth Hosp Q4 FY26
What went well
- FY26 Consolidated total income grew 34.6% to INR137 crores.
- FY26 EBITDA grew nearly 49% to INR58.8 crores, with margin expanding over 400 basis points to 42.9%.
- FY26 Profit attributable to shareholders increased 83% to INR25.8 crores.
What to watch
- H2 FY26 Uganda revenue dipped ~17% and PBT by ~46% due to Christmas break, elections, and infrastructure expenses.
- Delays in Tanzania facility licenses due to bureaucratic processes and elections.
What Unihealth Hosp does
UniHealth Hospitals Limited operates and manages multi-specialty tertiary-care hospitals and a dialysis centre under its 'UMC Hospitals' brand in Uganda and Tanzania, and has recently commissioned new hospitals in Navi Mumbai (operational) and Nashik (upcoming) in India. Alongside direct hospital operations, it runs a healthcare-consultancy vertical providing feasibility studies, hospital planning, project management and operations advisory to third-party healthcare projects in India and abroad. It also distributes and exports medical consumables and pharmaceuticals to African markets as an authorized distributor for companies such as Reliance Life Sciences and Fixderma India, and facilitates medical value travel for international patients seeking treatment at partner hospitals in India.
Segments
- Hospitals & Medical Centres
- Healthcare Consultancy
- Distribution & Trade
- Medical Value Travel
- Operational hospital beds
- ~400 (doubled from ~200 at start of FY26)
- Hospitals & medical facilities
- UMC Victoria Hospital, Kampala, Uganda (120 beds, est. 2017); Unihealth Medical Centre dialysis facility, Mwanza, Tanzania (10 beds, est. 2016); Navi Mumbai hospital (52 beds, opened Oct 2025); Nashik hospital (200 beds, commissioning FY27); Entebbe, Uganda hospital (acquired FY26)
- Countries of operation
- 3 (India, Uganda, Tanzania), after exiting Nigeria (UMC Zhahir Hospital, Kano)
- Doctors & specialists
- 150+
- Employees
- 500+
- Patients treated annually
- 1,30,000+
Guidance record · Q4 FY26
what the last two calls moved 16 tracked 1 delivered 1 missed 14 open- Navi Mumbai Hospital Operational Start delivered said Q4 FY25 Promised: Expected to begin operations by July 2025 Q4 FY26: Facility became fully operational in mid-February 2026. This fulfills the promise, though later than the original July 2025 target.
- Uganda ARPOB went quiet said Q2 FY26 Promised: 55,000 to 60,000 in the next 12 months Q4 FY26: No update provided on the current Uganda ARPOB or progress towards the 55k-60k target set for the next 12 months (by Q2 FY27).
- Total Operational Beds delayed said Q4 FY25 Promised: Cross 1,000 commissioned and operational beds under India and East Africa in the coming 3 years Q4 FY26: Target timeline pushed from CY27 to CY28. Company now targets 1,000 commissioned beds by CY28.
All 16 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q4 FY26: revenue up 140.7%, net profit up 183.3% against the same quarter last year.
| Line item | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 22 | 27 | 43 | 56 | 67 +205% | 65 +141% |
| EBITDA | 7 | 10 | 15 | 21 | 32 +357% | 22 +120% |
| Net profit | 4 | 6 | 9 | 18 | 29 +625% | 17 +183% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +324.9% 1Y
1Y: ₹167.55 on 10 Sept 2025 → ₹712. High ₹807.35 (3 Aug 2026), low ₹151.9 (26 Sept 2025).
How the price took the results
close before → close after
- Q4 FY26
- +4.9%
- 3 Jun
- Q2 FY26
- +18.3%
- 18 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹15 Cr | ₹16 Cr | ₹16 Cr |
| Reserves | ₹9 Cr | ₹13 Cr | ₹26 Cr | ₹70 Cr | ₹110 Cr | ₹122 Cr |
| Borrowings | ₹39 Cr | ₹38 Cr | ₹39 Cr | ₹15 Cr | ₹18 Cr | ₹33 Cr |
| Other liabilities | ₹9 Cr | ₹12 Cr | ₹12 Cr | ₹10 Cr | ₹78 Cr | ₹84 Cr |
| Total liabilities | ₹58 Cr | ₹65 Cr | ₹78 Cr | ₹110 Cr | ₹221 Cr | ₹254 Cr |
| Fixed assets | ₹35 Cr | ₹36 Cr | ₹37 Cr | ₹36 Cr | ₹72 Cr | ₹84 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹10 Cr | ₹10 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹22 Cr | ₹28 Cr | ₹41 Cr | ₹74 Cr | ₹139 Cr | ₹160 Cr |
| Total assets | ₹58 Cr | ₹65 Cr | ₹78 Cr | ₹110 Cr | ₹221 Cr | ₹254 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
Since Mar 2025, the public trimmed −0.84 pp while promoters added +0.60 pp. The shareholder count grew 18% to 1,162.
- Promoters
- 69.5%
- DIIs
- 0.5%
- Public
- 30.0%
Since Mar 2025
- Public −0.84 pp
- Promoters +0.60 pp
- DIIs +0.25 pp
How it drifted, 6 quarters
Over this window the public went from 22.3% to 30.0% — +7.7 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 68.8%, FIIs 5.6%, DIIs 3.3%, Public 22.3%.Mar '24: Promoters 68.8%, DIIs 0.1%, Public 31.1%.Sep '24: Promoters 68.9%, DIIs 0.0%, Public 31.1%.Mar '25: Promoters 68.9%, DIIs 0.2%, Public 30.8%.Sep '25: Promoters 69.1%, DIIs 0.8%, Public 30.1%.Mar '26: Promoters 69.5%, DIIs 0.5%, Public 30.0%.
Who bought this quarter
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Mona Laroia newly disclosed 1.94% held
- Huf newly disclosed 0.52% held
- Akshay Mahendra Parmar +0.29 pp 27.58% held
- Anurag Ratan Kumar Shah +0.22 pp 32.80% held
The same filing shows 3 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of Unihealth Hosp above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Anurag Ratan Kumar Shah | 32.80% | +0.22 pp |
| Akshay Mahendra Parmar | 27.58% | +0.29 pp |
| Prafulla Mahendra Parmar | 5.22% | −0.07 pp |
| Shantilal Bhikchand Kataria | 2.43% | unchanged |
| Mona Laroia | 1.94% | newly disclosed |
| Mukesh Sharma | 1.71% | −0.44 pp |
| Thermo Capital Private Limited | 1.42% | −0.31 pp |
| Sangeeta Shah | 0.88% | unchanged |
| Mayuri Akshay Parmar | 0.62% | unchanged |
| Huf | 0.52% | newly disclosed |
| Anant Wealth Consultants | — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 8.4% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
All earnings calls (3)
Read the Q4 FY26 call →Learn to analyse Unihealth Hosp
Guides on how to read this kind of business and the numbers that matter.